hotspot -WSS

hotspot

author：entertainment 2025-09-02 11:41:10 - browse：949

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Citing H5N1 threat, CDC urges peak flu monitoring this summer

entertainment

knowledge

WSS

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

How the drug

Study finds gene variants tied to breast cancer risk in Black women

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

PBMs are inflating the cost of generic drugs. They must be reined in

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA poised to publish guidelines for clinical trial diversity

23andMe had bad news about my health. I wish a person had delivered it

Trans patients at the end of life deserve respect and dignity

Anesthesiologist group: stop taking Ozempic before surgery

People can get long Covid without testing positive for virus: Study

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

At flashy new research hub, AstraZeneca lays out ambitious growth goals

United colonoscopy coverage change 'may cost lives,' doctors say

Bird flu surveillance in wastewater gets boost from consortium

focus

At flashy new research hub, AstraZeneca lays out ambitious growth goals

As a primary care physician, here's how I hope to partner with AI

H5N1 virus can be tracked in retail milk, scientists say

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Eyeing GLP

How to make over

entertainment

entertainment

knowledge

knowledge